Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sangamo Biosciences Inc (SGMO)  
$0.52 0.04 (6.83%) as of 4:30 Wed 4/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 140,990,000
Market Cap: 73.88(M)
Last Volume: 2,041,307 Avg Vol: 1,748,484
52 Week Range: $0.2971 - $1.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 6,000,000 6,500,000
Total Sell Value $0 $0 $3,000,000 $5,657,240
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 3
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 539
  Page 18 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gregory Philip D SVP, Research & CSO   •       –      –    2015-01-02 4 AS $15.78 $236,664 D/D (15,000) 116,410     -
   Gregory Philip D SVP, Research & CSO   •       –      –    2015-01-02 4 OE $3.45 $110,120 D/D 15,000 131,410     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-15 5 GD $0.00 $0 I/I 2,000 1,189,021     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-15 4 AS $14.79 $384,912 D/D (25,000) 323,467     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-15 4 OE $4.11 $102,750 D/D 25,000 348,467     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-15 4 D $14.74 $1,422,723 D/D (96,533) 323,467     -
   Nichol Geoffrey Executive Vice President, R&D   •       –      –    2014-12-15 4 D $14.74 $615,217 D/D (41,743) 138,146     -
   Gregory Philip D Vice President, Research & CSO   •       –      –    2014-12-15 4 D $14.74 $448,587 D/D (30,437) 116,410     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-12-15 4 D $14.74 $405,006 D/D (27,480) 95,376     -
   Larson John William Director   –       •      –    2014-12-15 4 AS $16.28 $162,829 D/D (10,000) 214,660     -
   Larson John William Director   –       •      –    2014-12-15 4 OE $5.03 $89,250 D/D 15,000 229,660     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2014-12-15 4 D $14.74 $589,587 D/D (40,004) 210,849     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-11 4 A $0.00 $0 D/D 125,000 420,000     -
   Nichol Geoffrey Executive Vice President, R&D   •       –      –    2014-12-11 4 A $0.00 $0 D/D 37,500 179,889     -
   Gregory Philip D Vice President, Research & CSO   •       –      –    2014-12-11 4 A $0.00 $0 D/D 37,500 146,847     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-12-11 4 A $0.00 $0 D/D 25,000 122,856     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2014-12-11 4 OE $0.00 $0 D/D 37,500 250,853     -
   Mento Steven J Director   –       •      –    2014-12-11 4 AS $15.00 $95,310 D/D (6,354) 28,715     -
   Mento Steven J Director   –       •      –    2014-12-11 4 OE $4.10 $41,000 D/D 10,000 35,069     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-12-10 5 GD $0.00 $0 I/I 13,500 1,191,021     -
   Larson John William Director   –       •      –    2014-12-09 4 AS $12.00 $120,000 D/D (10,000) 214,660     -
   Larson John William Director   –       •      –    2014-12-09 4 OE $4.54 $45,400 D/D 10,000 224,660     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-12-05 4 AS $11.21 $168,197 D/D (15,000) 97,856     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-12-05 4 OE $6.82 $102,300 D/D 15,000 112,856     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-12-01 4 AS $11.68 $175,191 D/D (15,000) 109,347     -
  539 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us